SCHEMBL10119031

SCHEMBL10119031

C=C(C)[S+]([O-])c1ccc2nccc(Cl)c2c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 2/20 0.35
DOT1L Q8TEK3 1/20 0.35
NR4A2 P43354 1/20 0.33
AXL P30530 1/20 0.32
PRKCI P41743 1/20 0.32
KDM4E B2RXH2 2/20 0.31
MAPK1 P28482 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4009656 0.80 DYRK1B (0.39) DYRK1BDOT1LNR4A2AXLPRKCI
SCHEMBL12180675 0.79 DYRK1B (0.40) DYRK1BDOT1LNR4A2AXLPRKCI
SCHEMBL10123872 0.78 DYRK1B (0.37) DYRK1BDOT1LNR4A2AXLPRKCI
SCHEMBL10106297 0.77 DYRK1B (0.39) DYRK1BDOT1LNR4A2AXLPRKCI
SCHEMBL14730882 0.71 RIPK2 (0.38) DYRK1BNR4A2KDM4EMAPK1ALDH1A1
SCHEMBL10119033 0.71 MET (0.39) DYRK1BDOT1LNR4A2AXLPRKCI
SCHEMBL27470369 0.70 ALOX15 (0.37) DYRK1BNR4A2AXLPRKCIKDM4E
SCHEMBL27465861 0.70 KMT5B (0.35) DYRK1BNR4A2AXLPRKCIKDM4E
SCHEMBL1862289 0.70 DOT1L (0.50) DYRK1BDOT1LNR4A2AXLPRKCI
SCHEMBL15043774 0.68 SLC2A1 (0.53) DYRK1BDOT1LKDM4EMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041024-A1 QUINOLYL AMINES AS KINASE INHIBITORS ABL1, MAP3K20, MAP3K19 DYRK1B 175/4885DOT1L 119/4885NR4A2 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.